Piperidine derivatives which are compounds of formula (I) ##STR1## wherein Ar1 and Ar2 independently represent a phenyl group optionally substituted by a halogen atom, a thienyl group or a pyridinyl group, A represents an alkylene group of 2 to 6 carbon atoms, X represents a CO group or a bond, r1 represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, either r2 represents a hydrogen atom and r3 represents a hydrogen atom or a hydroxy group, or r2 and r3 together represent a bond, and r4 represents a hydrogen or halogen atom, or pharmaceutically acceptable acid addition salts thereof are useful as antiallergics and antipruritics.

Patent
   4680296
Priority
Oct 16 1984
Filed
Oct 15 1985
Issued
Jul 14 1987
Expiry
Oct 15 2005
Assg.orig
Entity
Large
27
3
EXPIRED
1. Piperidine derivatives which are compounds of formula (I) ##STR9## wherein Ar1 and Ar2 independently represent a phenyl group optionally substituted by a halogen atom, a thienyl group or a pyridinyl group, A represents an alkylene group of 2 to 6 carbon atoms, X represents a CO group or a bond, r1 represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, either r2 represents a hydrogen atom and r3 represents a hydrogen atom or a hydroxy group, or r2 and r3 together represent a bond, and r4 represents a hydrogen or halogen atom, or pharmaceutically acceptable acid addition salts thereof.
2. Derivatives according to claim 1, wherein Ar1 and Ar2 independently represent a 2-thienyl, 2-pyridinyl, phenyl or 4-fluorophenyl group, and r4 represents a hydrogen atom.
3. Derivatives according to claim 2 wherein r2 is a hydrogen atom and r3 is a hydroxy group.
4. Derivatives according to claim 3 wherein Ar1 denotes a 4-fluorophenyl group and Ar2 denotes a 4-fluorophenyl group or a 2-pyridinyl group.
5. A pharmaceutical composition which contains, as active ingredient, an effective amount of a piperidine derivative as claimed in claim 1 in association with a pharmaceutically acceptable excipient.

The present invention relates to piperidine derivatives, their preparation and to pharmaceutical compositions containing them.

The invention provides piperidine derivatives which are compounds of formula (I) ##STR2## wherein Ar1 and Ar2 independently represent a phenyl group optionally substituted by a halogen atom, a thienyl group or a pyridinyl group, A represents an alkylene group of 2 to 6 carbon atoms, X represents a CO group or a bond, R1 represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, either R2 represents a hydrogen atom and R3 represents a hydrogen atom or a hydroxy group, or R2 and R3 together represent a bond, and R4 represents a hydrogen or halogen atom, or pharmaceutically acceptable acid addition salts thereof.

The preferred piperidine derivatives of the invention are those in which Ar1 and Ar2 independently represent a 2-thienyl, 2-pyridinyl, phenyl or 4-fluorophenyl group and R4 represents a hydrogen atom, with the other symbols being as defined above.

Preferably R2 is a hydrogen atom and R3 is a hydroxy group. Also preferred are those derivatives wherein Ar1 denotes a 4-fluorophenyl group and Ar2 denotes a 4-fluorophenyl group or a 2-pyridinyl group.

According to the invention the piperidine derivatives are prepared by reacting a compound of formula (II) ##STR3## with a compound of formula (III) ##STR4## wherein Y is a halogen atom or a labile group and the various other symbols are as defined above, in a protic or aprotic solvent at a temperature of 25° to 120°C, and if desired converting the resulting compound of formula (I) into an acid addition salt in manner known per se.

When Y is a labile group it preferably is tosyl or mesyl. Suitable protic solvents are alcohols and suitable aprotic solvents include methyl isobutyl ketone.

Some of the compounds of formula (II) are described in U.S. Pat. No. 2,804,422 and in the literature by Duncan et al., J. Med. Chem. 13, 1, 1970.

Compounds (II) in which Ar1 or Ar2 represents a pyridinyl or phenyl group may be prepared by reacting a compound of formula (IV) ##STR5## wherein R is a protective group such as acetyl or benzyl, with an organometallic compound of formula (V)

Ar2 Li or Ar2 MgX (V)

and then hydrolyzing or hydrogenolyzing the resulting compound (VI) ##STR6## to produce a compound (II).

The compounds (III) are described in the literature, by Vernin et al., J. Het. Chem., 18, 85 (1981).

Compounds of formula (I) in which R2 =R3 =H may also be obtained by hydrogenolysis of compounds of formula (I) in which R2 =H and R3 =OH or hydrogenation of compounds of formula (I) in which R2 and R3 together represent a bond.

The compounds (I) in which X is CO, R1 =H and A is (CH2)2 may be prepared by reacting a compound of formula (VII) ##STR7## with a compound of formula (II) in a solvent such as toluene or methyl isobutyl ketone.

The compounds of formula (VII) are described in the literature.

The following Examples will serve to illustrate the invention.

The structures of the compounds were confirmed by analyses and IR and NMR spectra.

PAC 1-[2-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-ethyl]-1,3-dihydro-2(2H)-ben zimidazolone

A mixture of 2.7 g (0.01 mole) of alpha,alpha-diphenyl-4-piperidinemethanol, 2.4 g (0.01 mole) of 1-(1-bromo-2-ethyl)-2-benzimidazolone, 1.2 g of sodium carbonate (Na2 CO3), and a crystal of sodium iodide in 75 ml of methyl isobutyl ketone is heated at reflux temperature for 18 h.

The mixture is cooled and then evaporated to dryness. The evaporation residue is taken up with a mixture of water and chloroform and the organic phase is dried, filtered and evaporated. Compound (I) is obtained, which is recrystallized from an ethyl acetate/isopropyl ether (85/15) mixture. M.p.=193°-196°C

PAC 1-[2-[4-(Diphenylmethylene)-1-piperidinyl]-ethyl]-1,3-dihydro-2(2H)-benzimi dazolone

Methyl isobutyl ketone, 1.0 g (0.004 mole) of 4-(diphenylmethylene)piperidine, 0.96 g (0.004 mole) of 1-(1-bromo-2-ethyl)-2-benzimidazolone, 0.53 g (0.008 mole) of Na2 CO3 and a few crystals of NaI are heated for 9 h at the reflux temperature.

The solvent is evaporated off, the residue is taken up with water and methylene chloride, the reaction mixture is separated by gravity, and the organic phase is dried and evaporated. A yellow solid is obtained which is passed through a column of silica (eluant 97 CH2 Cl2 /3 MeOH). On evaporation a solid is collected which is recrystallized from ethyl acetate. M.p.=202°-203°C

PAC 1-[2-[4-Diphenylmethyl-1-piperidinyl]ethyl]-1,3-dihydro-2(2H)-benzimidazolo ne

A solution of 4 g of 1-[2-[4-diphenylmethylene-1-piperidinyl]ethyl]-1,3-dihydro-2(2H)-benzimida zolone in 150 cm3 of methanol is hydrogenated with the aid of a Parr apparatus, at ambient temperature, at a hydrogen pressure of 50 psi, in the presence of 5% palladium on charcoal. When the absorption of hydrogen has ended, the catalyst is filtered off and the filtrate is evaporated down. The product obtained is recrystallized from ethyl acetate. M.p.=195°-196°C

PAC 1-[2-[4-[Bis(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]-1,3-dihydro-2(2H)- benzimidazolone.

Methyl isobutyl ketone, 1.6 g (0.006 mole) of 1-(1-bromo-2-ethyl)-1,3-dihydro-2(2H)-benzimidazolone, 1.9 g (0.0066 mole) of bis(4-fluorophenyl)-4-methylpiperidine, 0.8 g (0.0075 mole) of Na2 CO3 and a few crystals of NaI are heated at reflux temperature for approximately 6 h. The solvent is evaporated off, the residue is taken up with a mixture of ether and water, the reaction mixture is allowed to undergo phase separation, and the ether phase is filtered and evaporated down. An oil is obtained which is crystallized from isopropyl ether. A pure white product is filtered off and dried. M.p.=104°-106° C.

PAC 1-[3-[4-[Bis-(4-fluorophenyl)hydroxymethyl]piperidinyl]propyl]-1,3-dihydro- 2(2H)-benzimidazolone

2.1 g (0.007 mole) of 4-[bis(4-fluorophenyl)hydroxymethyl]piperidine, 1.8 g (0.007 mole) of 1-(1-bromo-3-propyl)-1,3-dihydro-2(2H)-benzimidazolone, 0.85 g (0.008 mole) of Na2 CO3 and a few crystals of NaI are heated for 5 h at reflux temperature in 60 ml of methyl isobutyl ketone. The solvent is evaporated off, the residue is taken up with a mixture of water and CH2 Cl2, and the organic phase is dried and evaporated down. A solid residue is obtained which is chromatographed on a column of silica (eluent: CH2Cl2/MeOH 97/3, 96/4 and then 94/6). The pure fractions are evaporated down, the evaporation residue is taken up with ether and a white product is filtered off and crystallized from 90 ml of ethyl acetate. M.p.=141°-143°C

PAC 1-[2-[4-[(2-Pyridinyl)(phenyl)hydroxymethyl]piperidinyl]ethyl]-1,3-dihydro- 2(2H)-benzimidazolone PAC 1.1.1. 4-[(2-Pyridinyl)(phenyl)hydroxymethyl]-1-benzylpiperidine

2.1 ml (2.2 10-2 mole) of 2-bromopyridine in solution in 10 ml of tetrahydrofuran (THF) are added dropwise to a solution, cooled to -65°C, of 15.6 ml (2.5 10-2 mole) of n-BuLi and of 20 ml of THF. The mixture is stirred for 1/4 h at -65°C and then 5.6 g (2 10-2 mole) of 1-benzyl-4-benzoylpiperidine in 20 ml of THF are added dropwise while the temperature is maintained at -65°C The mixture is allowed to warm up very slowly and is then left overnight. It is heated to the reflux temperature for 2 h and then evaporated to dryness, and the residue is taken up with a mixture of water and ether. The ether phase is washed with water, dried, filtered and evaporated down. Chromatography on silica is carried out (eluent 95/5 CH2 Cl2 /MeOH). A product which crystallizes from petroleum ether is collected. M.p.= 142°-143°C

5.4 g (1.5 10-2 mole) of the derivative obtained previously, in solution in 50 ml of methanol containing 1 ml of acetic acid, are hydrogenated, in a Parr apparatus, at 40°C, in the presence of palladium on charcoal, at a pressure of 0.35 Mpa. When the absorption is finished, the catalyst is filtered off and the mixture is then evaporated to dryness.

The residue is taken up with a little water, made alkaline with sodium hydroxide and extracted with ether. It is dried, filtered and evaporated down.

The product, which crystallizes in isopropyl ether, is triturated. M.p.=125°-128°C

1.2. 1-[2-[4-[(2-Pyridinyl)(phenyl)hydroxymethyl]-1-piperidinyl]ethyl]-1,3-dihy dro-2(2H)-benzimidazolone

2.5 g (10-2 mole) of 4-[(2-pyridinyl)(phenyl)hydroxymethyl]piperidine, 2.5 g (10-2 mole) of 1-(1-bromo-2-ethyl)-1,3-dihydro-2(2H)-benzimidazolone, 1.2 g of Na2 CO3, one crystal of NaI and 75 ml of methyl isobutyl ketone are introduced into a round flask.

The mixture is maintained at reflux temperature for 4 h and is evaporated to dryness; the residue is taken up with a mixture of water and methylene chloride; the organic phase is dried, filtered and evaporated down. After trituration in ether, a product is obtained which is recrystallized from methyl ethyl ketone. M.p.=206°-207°C

PAC 3-[2-[4-[Diphenylhydroxymethyl]-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazoline dione

2 g (0.00748 mole) of 4-(diphenylhydroxymethyl)piperidine and 1.4 g (0.00748 mole) of 2,3-dihydro(2,5-b)(5H)oxazolo-5-quinolinone in 50 ml of toluene containing one drop of 7.5 N hydrochloric acid are introduced into a 100 ml three-necked round flask. The mixture is heated at 100°-120°C for 28 h.

The precipitate formed is filtered off, washed with a little toluene and dried. The compound is recrystallized from methanol. M.p.=206°-208°C

PAC 1-[3-[4-(Diphenylhydroxymethyl)-1-piperidinyl]propyl]-2,4-(1H,3H)-quinazoli nedione

2.7 g (0.01 mole) of 4-(diphenylhydroxymethyl) piperidine, 1.2 g (0.005 mole) of 1-(3-chloropropyl)-2,4(1H,3H)-quinazolinedione in 75 ml of ethanol are heated at reflux temperature for 7 h.

The precipitate is filtered off, taken up with a mixture of water and CHCl3, made alkaline with sodium hydroxide, stirred for half an hour and filtered off. The compound is recrystallized from pyridine. M.p.=248°-250°C

The compounds prepared by way of examples are shown in the following table.

TABLE
__________________________________________________________________________
##STR8##
Com-
pound
X A Ar1
Ar2
R1
R2
R3
R4
M.p (°C.)
__________________________________________________________________________
1 bond
(CH2)2
C6 H5
C6 H5
H H H H 195-196
2 bond
(CH2)2
C6 H5
C6 H5
H bond H 202-203
3 bond
(CH2)2
C6 H5
C6 H5
H H OH H 193-196
4 bond
(CH2 )2
C6 H5
C6 H5
CH3
H OH H 166-170
5 bond
(CH2)2
C6 H5
C6 H5
iPr
H OH H 140-142
6 bond
(CH2)3
C6 H5
C6 H5
H H OH H 180-182
7 bond
(CH2)4
C6 H5
C6 H5
H H OH H 95
8 bond
(CH2)5
C6 H5
C6 H5
H H OH H 114-117
9 bond
(CH2)2
4-FC6 H4
4-FC6 H4
H H H H 104-106
10 bond
(CH2)2
4-FC6 H4
4-FC6 H4
H H OH H 149-151
11 bond
(CH2)3
4-FC6 H4
4-FC6 H4
H H OH H 141-143
12 bond
(CH2)4
4-FC6 H4
4-FC6 H4
H H OH H 110
13 bond
(CH2)3
4-FC6 H4
C6 H5
H H OH H 138-140
14 bond
(CH2)3
4-FC6 H4
4-FC6 H4
H H H H 165-167
15 bond
(CH2)3
4-FC6 H4
4-FC6 H4
H bond H 171-172
16**
bond
(CH2)4
4-FC6 H4
4-FC6 H4
H H H H 210-212**
17 bond
(CH2)2
C6 H5
Pyrid-2
H H OH H 206-207
18 bond
(CH2)3
C6 H5
Pyrid-2*
H H OH H 201-203
19 bond
(CH2)3
4-FC6 H4
Pyrid-2
H H OH H 192-195
20 bond
(CH2)2
Thienyl-2
Thienyl-2
H H OH H 209-211
21 bond
(CH2)3
Thienyl-2
Thienyl-2
H H OH H 224-226
22 bond
(CH2)3
4-FC6 H4
Pyrid-2
H H OH H 192-195
23 bond
(CH2)4
4-FC6 H4
Pyrid-2
H H OH H 69
24 CO (CH2)2
C6 H5
C6 H5
H H OH H 206-208
25 CO (CH2)3
C6 H5
C6 H5
H H OH H 221-223
26 CO (CH2)4
C6 H5
C6 H5
H H OH H 207-208
27 CO (CH2)2
4-FC6 H4
4-FC6 H4
H H OH H 213-214
28 CO (CH2)3
4-FC6 H4
4-FC6 H4
H H OH H 209-212
29 bond
(CH2)2
C6 H5
C6 H5
CH3
H OH Cl
122-125
__________________________________________________________________________
*Pyrid = Pyridinyl
**melting point of the oxalate

The piperidine derivatives of the invention were subjected to various pharmacological tests to demonstrate their antagonist activity for histamine and for serotonin.

1. Activity in vitro: Isolated guinea-pig ileum

The test was carried out according to the Magnus method modified by Savini (Arch. Int. Pharmacodyn., 113, 157), on three-coloured male guinea-pigs weighing approximately 300 g, after 18 hours-fasting.

A fragment of ileum is removed, placed at 39°C in a tyrode bath at 39°C through which a stream of carbonating gas (95% O2, 5% CO2) is passing and connected to an isotonic sensor with a maximum tension of 2.5 g. The contractions are recorded by means of an Ugo Basile microdynamometer.

The contractions are induced by various spasmogenic agents for which the concentration causing a submaximal response is determined (histamine: 1 to 8 10-8 g/ml). The piperidine derivatives of the invention, dissolved in distilled water or a 0.1 N solution of methanesulfonic acid, are placed in contact with the ileum for 1 min before the introduction of the spasmogenic substance. The AC50 (concentration reducing by 50% the contractions induced by histamine) of certain piperidine derivatives of the invention range from 10-7 to 10-8 molar.

2. Activity in vivo: Inflammation induced by histamine or serotonin.

Intraplanar injection of histamine(200 μg)or of serotonin (1 μg) into one of the hind paws of the rat causes an oedema measured, 1 h after injection, with the aid of a mercury Ugo Basile plethysmometer.

The piperidine derivatives of the invention, suspended in a 1% solution of Tween in distilled water are administered p.o. (0.5 ml/100 g) 1 h before the injection of the inflammatory agent.

The AD40 (dose which reduces the volume of the oedema by 40%) are measured.

The piperidine derivatives of the invention have an AD40 ranging from 1 to 5 mg/kg when the inflammatory agent is histamine.

Some piperidine derivatives of the invention are active at an AD40 dose ranging from 0.2 to 1 mg/kg when the inflammatory agent is serotonin.

The piperidine derivatives of the invention may therefore be employed as antiallergics and antipruritics for the treatment of respiratory allergies, such as rhinitis and hay fever, skin allergies such as dermatitis and urticaria, eye allergies, Quincke's disease and various allergic manifestations.

The piperidine derivatives of the invention which are more specifically active as serotonin antagonists may be employed for combating some undesirable effects of this mediator in the peripheral system or in the central system. They are intended, in particular, for the treatment of migraine.

The invention consequently comprises all pharmaceutical compositions containing, as active ingredient, at least one piperidine derivative of the invention in association with a pharmaceutically acceptable excipient.

The administration routes may be oral or parenteral.

The daily dosage may range from 5 to 200 mg.

Manoury, Philippe, Binet, Jean, Dewitte, Elisabeth

Patent Priority Assignee Title
4831043, Feb 13 1987 AVENTIS PHARMA S A Dopaminergic benzimidazol-2-ones
5283243, Nov 24 1990 Solvay Pharmaceuticals GmbH Piperidinoalkylbenzoxazine and piperidinoalkylbenzothiazine compounds, and medicaments containing them
5563147, Sep 12 1994 Lilly Industries Limited Serotonerbic tetrahydropyridoindoles
5596003, Feb 13 1992 Merrell Pharmaceuticals Inc Piperidinyl thiacyclic derivatives
5602147, Feb 13 1992 Merrell Pharmaceuticals Inc Piperidinyl thiacyclic derivatives
5605900, Feb 18 1993 Kyowa Hakko Kogyo Co., Ltd. Benzotriazines having adenosine uptake inhibitor activity
5631268, Feb 13 1992 Merrell Pharmaceuticals Inc Piperidinyl thiacyclic derivatives
5648353, Feb 18 1993 Kyowa Hakko Kogyo Co., Ltd. Quinazolines and phthalazines having adenosine uptake inhibitor activity
5650416, Feb 13 1992 Merrell Pharmaceuticals Inc Piperidinyl thiacyclic derivatives
5652246, Oct 21 1994 LES LABORATOIRES SERVIER Piperidine compounds
5658917, Feb 18 1993 Kyowa Hakko Kogyo Co., Ltd. Isoquinolines having adenosine uptake inhibitor activity
5739150, Feb 13 1992 AVENTIS INC Piperidinyl thiacyclic derivatives
5773448, Dec 19 1995 Eli Lilly and Company Limited Pharmaceutical compounds
6075039, Jun 26 1996 Eli Lilly and Company Limited 5HT receptor binding benzimidazolylpiperidines
6153626, Dec 20 1996 ASTRAZENECA CANADA INC Compounds with analgesic effect
6399635, Dec 20 1996 AstraZeneca Canada Inc. Compounds with analgesic effect
6710179, Dec 20 1996 AstraZeneca Canada Inc. Compounds with analgesic effect
6875777, Dec 20 1999 AstraZeneca AB Compounds
6974825, Dec 20 1996 AstraZeneca Canada Inc. Compounds with analgesic effect
7008952, May 18 2001 AstraZeneca AB 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
7064137, May 18 2001 AstraZeneca AB 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivaties and their use for the treatment of pain, anxiety or gastrointestinal disorders
7186733, May 18 2001 AstraZeneca AB 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
7226933, May 18 2001 AstraZeneca AB 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
8865727, Feb 29 2008 VM Therapeutics LLC Method for treating pain syndrome and other disorders
8980900, Feb 29 2008 VM Therapeutics, LLC. Method for treating pain syndrome and other disorders
9402848, Feb 29 2008 VM Therapeutics LLC Method for treating pain syndrome and other disorders
9834555, Feb 29 2008 VM Therapeutics LLC. Method for treating pain syndrome and other disorders
Patent Priority Assignee Title
3879393,
4016166, Dec 14 1973 TROPONWERKE GMBH & CO , KG 1-Nitrophenylquinazoline-2,4(1H,3H)-diones
4588722, Jan 09 1984 JANSSEN PHARMACEUTICA N V , A CORP OF BELGIUM N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Oct 02 1985MANOURY, PHILIPPESynthelaboASSIGNMENT OF ASSIGNORS INTEREST 0044820795 pdf
Oct 02 1985BINET, JEANSynthelaboASSIGNMENT OF ASSIGNORS INTEREST 0044820795 pdf
Oct 02 1985DEWITTE, ELISABETHSynthelaboASSIGNMENT OF ASSIGNORS INTEREST 0044820795 pdf
Oct 15 1985Synthelabo(assignment on the face of the patent)
Date Maintenance Fee Events
Feb 12 1991REM: Maintenance Fee Reminder Mailed.
Jul 14 1991EXP: Patent Expired for Failure to Pay Maintenance Fees.


Date Maintenance Schedule
Jul 14 19904 years fee payment window open
Jan 14 19916 months grace period start (w surcharge)
Jul 14 1991patent expiry (for year 4)
Jul 14 19932 years to revive unintentionally abandoned end. (for year 4)
Jul 14 19948 years fee payment window open
Jan 14 19956 months grace period start (w surcharge)
Jul 14 1995patent expiry (for year 8)
Jul 14 19972 years to revive unintentionally abandoned end. (for year 8)
Jul 14 199812 years fee payment window open
Jan 14 19996 months grace period start (w surcharge)
Jul 14 1999patent expiry (for year 12)
Jul 14 20012 years to revive unintentionally abandoned end. (for year 12)